Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

Eli Lilly received FDA approval last July for Kisunla (generic name donanemab), a treatment that removes amyloid plaque accumulation in the brain. Domestic researchers have developed a new system ...

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...

“The problem with the Alzheimer’s group is they were very co-opted,” said Peter J. Whitehouse, MD, PhD, a professor of ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Recent approvals, such as LEQEMBI (lecanemab) by Biogen and Eisai, Eli Lilly's KISUNLA (donanemab-azbt), and Brexpiprazole (REXULTI), signify a shift toward more tailored therapeutic options.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.